Zolmitriptan

Zolmitriptan

SCHEMBL1246512

CN(C)CCc1c[nH]c2ccc(CC3COC(=O)N3)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HTR1BHTR1D

The experimentally established mechanism targets of Zolmitriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR1D known ✓ P28221 11/20 1.00
HTR1B known ✓ P28222 11/20 1.00
HTR1A P08908 10/20 1.00
HTR2A P28223 5/20 1.00
KMT2A Q03164 1/20 1.00
ADRA1A P35348 1/20 1.00
HTR1F P30939 2/20 0.63
HTR5A P47898 4/20 0.54
HTR2C P28335 3/20 0.54
HTR2B P41595 2/20 0.54
HTR1E P28566 1/20 0.54
HTR7 P34969 1/20 0.54
HTR3A P46098 1/20 0.54
SLC47A1 Q96FL8 1/20 0.54
SCN9A Q15858 1/20 0.54
LMNA P02545 1/20 0.53
ADRA2B P18089 1/20 0.53
KCNH2 Q12809 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Zolmitriptan SCHEMBL29835946 1.00 HTR1D (1.00) HTR1DHTR1BHTR1AHTR2AKMT2A
Zolmitriptan SCHEMBL14861150 1.00 HTR1D (1.00) HTR1DHTR1BHTR1AHTR2AKMT2A
Zolmitriptan SCHEMBL40595 1.00 HTR1D (1.00) HTR1DHTR1BHTR1AHTR2AKMT2A
Zolmitriptan SCHEMBL29356689 1.00 HTR1D (1.00) HTR1DHTR1BHTR1AHTR2AKMT2A
Zolmitriptan SCHEMBL33336 1.00 HTR1D (1.00) HTR1DHTR1BHTR1AHTR2AKMT2A
Zolmitriptan SCHEMBL4427888 1.00 HTR1D (1.00) HTR1DHTR1BHTR1AHTR2AKMT2A
Zolmitriptan SCHEMBL2377949 0.99 HTR1D (0.98) HTR1DHTR1BHTR1AHTR2AKMT2A
Zolmitriptan SCHEMBL2458156 0.99 HTR1D (0.98) HTR1DHTR1BHTR1AHTR2AKMT2A
Zolmitriptan SCHEMBL2540996 0.96 HTR1D (0.92) HTR1DHTR1BHTR1AHTR2AKMT2A
Zolmitriptan SCHEMBL2376692 0.95 HTR1D (0.90) HTR1DHTR1BHTR1AHTR2AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118095-B1 A METHOD FOR THE PREPARATION OF ZOLMITRIPTAN ZENTIVA KS (CZ) 2010-11-03 EP claimed
US-20100145064-A1 METHOD FOR THE PREPARATION OF ZOLMITRIPTAN ZENTIVA K.S. (CZ) 2010-06-10 US claimed
US-20100105919-A1 METHOD FOR THE PREPARATION OF ZOLMITRIPTAN ZENTIVA K.S. (CZ) 2010-04-29 US claimed
EP-2125798-A2 A METHOD FOR THE PREPARATION OF ZOLMITRIPTAN Zentiva, k.s. (CZ) 2009-12-02 EP claimed
WO-2008104134-A2 A METHOD FOR THE PREPARATION OF ZOLMITRIPTAN ZENTIVA, A.S. (CZ) 2008-09-04 WO claimed
US-20070173536-A1 Crystalline forms of zolmitriptan CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2007-07-26 US claimed
EP-1711493-A2 CRYSTALLINE FORMS OF ZOLMITRIPTAN CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement (CH) 2006-10-18 EP claimed
WO-2005075467-A2 CRYSTALLINE FORMS OF ZOLMITRIPTAN CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2005-08-18 WO claimed
EP-0636623-B1 Indole derivatives as 5-HT1- like agonists ASTRAZENECA AB (SE) 2001-08-16 EP claimed
US-6160123-A One pot synthesis of 2-oxazolidinone derivatives ZENECA, LTD. (GB) 2000-12-12 US claimed
EP-0843672-A1 ONE POT SYNTHESIS OF 2-OXAZOLIDINONE DERIVATIVES ZENECA LIMITED (GB) 1998-05-27 EP claimed
EP-0486666-B1 THERAPEUTIC HETEROCYCLIC COMPOUNDS ZENECA LTD (GB) 1997-08-13 EP claimed
WO-1997006162-A1 ONE POT SYNTHESIS OF 2-OXAZOLIDINONE DERIVATIVES ZENECA LIMITED (GB) 1997-02-20 WO claimed
WO-1996041633-A1 METHODS OF TREATING COLD AND ALLERGIC RHINITIS ELI LILLY AND COMPANY (US) 1996-12-27 WO claimed
EP-0747049-A1 Use of tachykinin antagonists in combination with serotonin agonists or serotonin reuptake inhibitors for the manufacture of a medicament for the treatment of allergic rhinitis ELI LILLY AND COMPANY (US) 1996-12-11 EP claimed
WO-1996029074-A1 METHODS OF TREATING OR PREVENTING PAIN OR NOCICEPTION ELI LILLY AND COMPANY (US) 1996-09-26 WO claimed
EP-0710479-A1 Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine ELI LILLY AND COMPANY (US) 1996-05-08 EP claimed
WO-1996011000-A1 METHODS OF TREATING MIGRAINE ELI LILLY AND COMPANY (US) 1996-04-18 WO claimed
US-5466699-A Indolyl compounds for treating migraine BURROUGHS WELLCOME CO. (US) 1995-11-14 US claimed
EP-0636623-A1 Indole derivatives as 5-HT1- like agonists THE WELLCOME FOUNDATION LIMITED (GB) 1995-02-01 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105919-A1 METHOD FOR THE PREPARATION OF ZOLMITRIPTAN SOST, SFRP1, FZD7 HTR1D 9/4885HTR1B 44/4885HTR1A 116/4885
US-20070173536-A1 Crystalline forms of zolmitriptan LIPA, LPXN, CETP HTR1D 29/4885HTR1B 120/4885HTR1A 82/4885
US-20100145064-A1 METHOD FOR THE PREPARATION OF ZOLMITRIPTAN LPXN, TREH, HTR3A HTR1D 148/4885HTR1B 191/4885HTR1A 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.